Senhwa Biosciences Highlights AI-Validated Oncology Platform and Strategic Clinical Collaborations Targeting Next-Generation Immuno-Oncology products at Its 2025 Annual Investor Conference
TAIPEI and SAN DIEGO, Dec. 23, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage companies focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today outlined...
Global study targets dengue as disease threatens nearly half the world's population
LISMORE, Australia, Dec. 18, 2025 /PRNewswire/ -- Thousands of dengue forecasting models have been published, but few have been tested in real public-health settings. Now, researchers from the US and Australia are launching a field evaluation in...
Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy
TAIPEI and SAN DIEGO, Oct. 21, 2025 /PRNewswire/ -- Senhwa Biosciences's investigational new drug Silmitasertib (CX-4945) was recently featured in an official post by Google DeepMind, following a major breakthrough by the tech giant's biological...